Research
Hormonal
Intensive glycemic control (HbA1c <6.5%) in the first year after diagnosis of Type 2 Diabetes significantly reduces the 10-year risk of microvascular and macrovascular complications compared to higher HbA1c levels.
If you were just diagnosed with Type 2 Diabetes, ask your doctor about getting your blood sugar under tight control (HbA1c <6.5%) as soon as possible. This early, intensive treatment significantly reduces your risk of developing serious complications like kidney disease, heart problems, and vision loss over the next 10 years.
GoodSupportsHIGH confidence
Analysis of the data of the real-world Diabetes & Aging study [7] involving close to 35.000 people with T2DM showed that compared with the attainment of a hemoglobin A1c (HbA1c) <6.5% during the first year after diagnosis, the 10-yr risk of developing microvascular and macrovascular complications increased proportionally in those with higher HbA1c levels suggesting that immediate, intensive treatment for newly diagnosed patients is necessary.
Why this rating
Based on real-world data from the Diabetes & Aging study and UKPDS follow-up.
Source
Cardio‐renal‐metabolic disease in primary care setting
Mahmoud Ibrahim et al. · Diabetes/Metabolism Research and Reviews · 2023
DOI 10.1002/dmrr.3755
narrative_reviewCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with type 2 diabetes, regardless of baseline ejection fraction or diabetes status.Strong
- GLP-1 receptor agonists (GLP1RAs) and SGLT2 inhibitors should be used as first-line treatment in patients with Type 2 Diabetes and initial kidney disease, combined with Metformin.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →